Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lingdi Zhao

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Immunity & Ageing : I & A|December 16, 2023
The inter-link of ageing, cancer and immunity: findings from real-world retrospective studyXiaomin Fu, Peng Qin, Fanghui Li, et al.
Frontiers in Oncology|September 26, 2022
Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancerBaozhen Ma, Yu Zhou, Yiman Shang, et al.
Journal of Hematology & Oncology|February 5, 2016
Autologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancerZibing Wang, Yuqing Liu, Rui'e Li, et al.
Scientific Reports|May 20, 2025
The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosisXiaomin Fu, Fanghui Li, Hongqin You, et al.
Cancer Immunology, Immunotherapy : CII|July 30, 2022
Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapyMengchao An, Wenkang Wang, Jie Zhang, et al.
Frontiers in Immunology|January 21, 2022
High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center StudyLingdi Zhao, Tiepeng Li, Yongping Song, et al.
Frontiers in Immunology|August 1, 2022
Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced MalignanciesHao Huang, Ling Peng, Bicheng Zhang, et al.
Frontiers in Immunology|December 23, 2021
The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II StudyWenqun Xing, Lingdi Zhao, Yan Zheng, et al.
Cancer Research|January 7, 2021
T Cells Expanded from PD-1<sup>+</sup> Peripheral Blood Lymphocytes Share More Clones with Paired Tumor-Infiltrating LymphocytesTiepeng Li, Lingdi Zhao, Yonghao Yang, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Immunity & Ageing : I & A|December 16, 2023
The inter-link of ageing, cancer and immunity: findings from real-world retrospective studyXiaomin Fu, Peng Qin, Fanghui Li, et al.
Frontiers in Oncology|September 26, 2022
Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancerBaozhen Ma, Yu Zhou, Yiman Shang, et al.
Journal of Hematology & Oncology|February 5, 2016
Autologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancerZibing Wang, Yuqing Liu, Rui'e Li, et al.
Scientific Reports|May 20, 2025
The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosisXiaomin Fu, Fanghui Li, Hongqin You, et al.
Cancer Immunology, Immunotherapy : CII|July 30, 2022
Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapyMengchao An, Wenkang Wang, Jie Zhang, et al.
Frontiers in Immunology|January 21, 2022
High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center StudyLingdi Zhao, Tiepeng Li, Yongping Song, et al.
Frontiers in Immunology|August 1, 2022
Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced MalignanciesHao Huang, Ling Peng, Bicheng Zhang, et al.
Frontiers in Immunology|December 23, 2021
The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II StudyWenqun Xing, Lingdi Zhao, Yan Zheng, et al.
Cancer Research|January 7, 2021
T Cells Expanded from PD-1<sup>+</sup> Peripheral Blood Lymphocytes Share More Clones with Paired Tumor-Infiltrating LymphocytesTiepeng Li, Lingdi Zhao, Yonghao Yang, et al.
Pageof 6